Recruiting

Glucoraphanin & Sulforaphane

Sponsor:

Oregon State University

Code:

NCT07564674

Conditions

Diet, Healthy

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Interventions

Avmacol Extra Strength with coating - 1 tablet

Avmacol chewable wafer - 2 tablets

Avmacol Extra Strength with coating - 2 tablets

Study Details

Brief summary:

The goal of this clinical trial is to compare how much glucoraphanin and sulforaphane from 3 different versions of broccoli extract supplements is absorbed into the body and excreted in urine. This study involves generally healthy adults age 18-60 years. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention.

Participants will:

  • consume 3 different versions of broccoli extract supplements (glucoraphanin will range from 35-70 mg)
  • complete 3 separate 24 hour study cycles
  • submit blood and urine samples for 24 hours
  • follow diet restrictions (no cruciferous vegetables or condiments or phytochemical/herbal supplements for 1 week prior to and during each study cycle)

Conditions

Diet, Healthy

Study ID

NCT07564674

Start date

Aug 4, 2026

Status verified date

Aug, 2026

Completion date

Sep, 2028

Anticipated

Primary completion date

Sep, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Healthy adults, 18-60 years of age
  • Willing to stop taking herbal and phytochemical (plant-based extract or phytochemical) supplements for 1 week prior to and during each study cycle
  • Willing to stop cruciferous vegetable intake 1 week prior to and during each study cycle
  • Must be able to give written informed consent

Exclusion Criteria:

  • Body Mass Index (BMI) <18.5 or >30.0 kg/m2
  • Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in the past three months
  • Pregnancy, breastfeeding, or planning to become pregnant before completing the study
  • Engaging in vigorous exercise more than 7 hours per week
  • Have a significant acute or chronic illness such as cardiovascular disease, kidney or liver disease, diabetes, thyroid disorder, or radiation or chemotherapy treatment for cancer within the past five years
  • Use of medications to control cholesterol (e.g. statins, cholestyramine) or fat absorption (e.g. orlistat)
  • Have had bariatric surgery (e.g. gastric bypass, gastric banding, sleeve gastrectomy, etc.), other gastrointestinal procedure (e.g. cholecystectomy) or disorders (e.g. Crohn's disease, celiac disease, ulcerative colitis)
  • Allergic to broccoli, moringa, mustard, or maitake mushrooms
  • Weighs less than 110 pounds
  • Diagnosis of sickle cell disease

Study Design

Enrollment

12 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

active comparator: 35 mg glucoraphanin

Participants will swallow by mouth 1 tablet of Avmacol Extra Strength with coating.

active comparator: 60 mg glucoraphanin

Participants will chew and swallow by mouth 2 tablets of Avmacol chewable wafers (30 mg glucoraphanin each)

active comparator: 70 mg glucoraphanin

Participants will swallow by mouth 2 tablets of Avmacol Extra Strength with coating (35 mg glucoraphanin each)

Interventions

Avmacol Extra Strength with coating - 1 tablet

Participants will swallow by mouth 1 tablet Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)

Avmacol chewable wafer - 2 tablets

Participants will chew and swallow by mouth 2 wafers Avmacol chewable wafers (30 mg glucoraphanin per wafer)

Avmacol Extra Strength with coating - 2 tablets

Participants will swallow by mouth 2 tablets Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)

Primary outcome measure

  • Urine sulforaphane [ Time Frame: 0, 2, 4, 8, and 24 hours ]
  • Urine sulforaphane metabolites [ Time Frame: 0, 2, 4, 8, and 24 hours ]
  • Plasma glucoraphanin [ Time Frame: 0, 1, 2, 4, 8, and 24 hours ]
  • Plasma sulforaphane [ Time Frame: 0, 1, 2, 4, 8, and 24 hours ]
  • Plasma sulforaphane metabolites [ Time Frame: 0, 1, 2, 4, 8, and 24 hours ]

Central Contacts and Locations

Central contacts

Emily Ho, PhD

541-737-9559emily.ho@oregonstate.edu

Sandra Uesugi, RN, BSN, MS

541-737-3594sandra.uesugi@oregonstate.edu

Locations

Oregon State University

Recruiting

Corvallis, Oregon, United States, 97331

Contacts

Sandra Uesugi, RN, BSN, MS

541-737-3594sandra.uesugi@oregonstate.edu

Principal Investigator:

Emily Ho, PhD

More Information

Sponsor

Oregon State University

Last update posted

Aug 7, 2026

Last verified

Aug, 2026

Keywords

  • cruciferous vegetable
  • broccoli extract supplement
  • glucoraphanin
  • sulforaphane

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Oregon State University on 2026-08-07.